Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Galectin Therapeutics Inc (NASDAQ:GALT)

2.22
Delayed Data
As of 3:59pm ET
 +0.26 / +13.27%
Today’s Change
1.68
Today|||52-Week Range
6.60
-36.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$44.7M

Company Description

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Contact Information

Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
P:(678) 620-3186
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Peter G. TraberPresident, CEO, Director & Chief Medical Officer
Harold H. ShlevinChief Operating Officer & Secretary
Jack W. CallicuttChief Financial Officer
Eliezer ZomerExecutive VP-Manufacturing & Product Development
J. Rex HortonExecutive Director-Regulatory Affairs